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Abstract
Purpose
Medication discrepancies are defined as unexplained differences among regimens across
different sites of care. The problem of medication discrepancies that occur during the entire
care pathway from hospital admission to a local care setting discharge (namely all types of
settings dedicated to formal care other than hospitals) has received little attention in the
medical literature.
The present study aims to (1) determine the prevalence of medication discrepancies that
occur during the entire care pathway from hospital admission to local care setting discharge,
(2) describe the discrepancy and medication type, and (3) identify potential risk factors for
experiencing medication discrepancies in patient care transitions. Evidence from an inte-
grated health care system, such as the Italian one, may explain results from other studies in
different healthcare systems.
Methods
A retrospective longitudinal cohort study of patients admitted from July 2015 to July 2016 to
the Giovanni Bosco Hospital serving Turin, Italy and its surrounding territory was performed.
Discrepancies were recorded at the following four care transitions: T1: Hospital admission;
T2: Hospital discharge; T3: Admission into local care settings; T4: Discharge from local care
settings. All evaluations were based on documented regimens and were performed by a
team (doctor, nurse and pharmacists).
Results
Of 366 included patients, 25.68% had at least one discrepancy. The most frequent type of
discrepancy was from medication omission (N = 74; 71.15%). Only discharge from a long-
stay care setting (T4) was significantly associated with the onset of discrepancies (p =
0.045). When considering a lack of adequate documentation, not as missing data but as a
discrepancy, 43.72% of patients had at least one discrepancy.
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Conclusions
This study suggests that an integrated health care system, such as Italian system, may influ-
ence the prevalence of discrepancies, thus highlighting the need for structured multidisci-
plinary and, if possible, computerized medication reconciliation to prevent medication
discrepancies and improve the quality of medical documentation.
Introduction
Medication discrepancies are defined as unexplained differences among regimens across dif-
ferent sites of care [1]. They are categorized into documented and undocumented discrepan-
cies, the latter of which are further subdivided into intentional or unintentional.
Recent scientific evidence considers medication discrepancies to be an important public
health problem with clinical and economic consequences [2–4]. Indeed, discrepancies can be
harmful, leading to inadequate prescriptions, interruptions of treatment, adverse drug events,
longer hospital stays and an increase in hospital readmissions and emergency room visits,
which are expensive for the health care system [2–7]. Several studies have identified care tran-
sitions as time points with a greater risk of drug discrepancies [8–10]. Additionally, medication
discrepancies in care transitions could occur more easily in the absence of a formalized system
for medication reconciliation and with poor quality of communication between primary and
secondary care [2].
Medication reconciliation is a formal process that involves matching the medicines that the
patient should be prescribed with those that are actually prescribed and involves adequately
reporting any therapy change [3,11]. Medication reconciliation has been identified in the liter-
ature as an important tool for preventing pharmacological discrepancies and the World Health
Organization, in the “Action on Patient Safety”, considers medication reconciliation to be one
of the five top strategies for ensuring patient safety [12]. Additionally, the Joint Commission
on Accreditation of Healthcare Organizations included medication reconciliation in the
accreditation standards [13]. The problem of medication discrepancies that occur during the
entire care pathway from hospital admission to a local care setting discharge (namely, all types
of settings dedicated to formal care other than hospitals) has received little attention in the
medical literature. Indeed, there are studies in the literature on single points of transitions of
care: most analyze discrepancies upon hospital admission or discharge [3,4,14–18], and little is
known about the prevalence of medication discrepancies upon admission or discharge from
local care settings, such as the home and rehabilitation facilities [1,19]. According to the litera-
ture unintended medication discrepancies occurred in 25%-70% of hospital admissions and in
33%-96% of hospital discharges [4,6,20–22] and up to 71% of patients admitted to local care
settings [1,19].
Current evidence is limited in Italy, and there are no studies conducted in a local care set-
ting [11].
New evidence may be important from an integrated health care system, such as the Italian
health system, and may help to explain results from other studies in other countries with dif-
ferent healthcare systems. Italy’s healthcare system is a regionally organized national health
service (Servizio Sanitario Nazionale, SSN) that has two underlying principles. First, every Ital-
ian citizen and foreign resident has the right to healthcare, and second, the system covers all
necessary treatments. Local health authorities (ASL) are responsible for the management of all
health services in their area, from prevention to care in hospitals and in any type of setting
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dedicated to formal care other than hospital care and located in the districts. Italy’s healthcare
system has made considerable efforts to achieve co-ordination and integration of care, which
allows the patient to be followed throughout his/her care pathway. For this aim, one unit in
hospitals (NOCC) and one in the district (NDCC) that oversee all transitions of care to manage
the most complex medical cases and to ensure the admission to and discharge from a health-
care setting were introduced. With Recommendation 17 [23], the Ministry expects that during
this pathway attention will also be devoted to pharmacological reconciliation.
The present study aims to (1) determine the prevalence of medication discrepancies that
occur during the entire care pathway from hospital admission to a local care setting discharge,
(2) describe the type of discrepancy and type of medication, and (3) identify potential risk fac-
tors for experiencing medication discrepancies during patient care transitions.
Methods
A retrospective longitudinal cohort study of patients admitted to the Giovanni Bosco Hospital
which serves Turin, Italy and its surrounding territory was performed. The following four
local care settings: (i) Long-stay Care, (ii) Rehabilitation, (iii) Supported discharge in multiple
facilities and (iv) Integrated Home Care (ADI), were studied. Giovanni Bosco Hospital is a
hub urban hospital in Turin in Local Health Authority ASL TO2, with more than 3400 health
workers and approximately 330 beds and 11,000 discharges/year. It covers an area of over
420,000 inhabitants. Local care setting were positioned in Turin city and on its surrounding
territory [24,25]. The study included all patients admitted to the Giovanni Bosco Hospital
from July 2015 to July 2016 who met the following inclusion criteria: (i) age> 18 years, (ii) dis-
charged from one of the four hospital wards (internal medicine, geriatrics, neurology, and
orthopedics), (iii) admitted to and discharged from one of the four local care settings indicated
above, and (iv) beginning and closing their clinical pathway during the above-cited period.
Discrepancies, defined as any undocumented and unintentional incongruity between the
documented sources that could result in therapy errors [11,14], were recorded for the follow-
ing four care transitions: T1: hospital admission; T2: hospital discharge; T3: admission to local
care setting; T4: discharge from local care setting. Medication discrepancies were identified
using a structured tool that retraces the medication reconciliation process and uses the same
variables and sources of documented regimens defined by Ministero della Salute Recommen-
dation [23]. Supported by the above cited recommendation, this analysis was conducted by a
team of all professional categories involved in medication treatment (a medical doctor, a nurse
and two clinical pharmacists, able to evaluate if the decided treatments were according to the
patient clinical pathway) in the following way. For T1, the emergency department (ED) list
recorded on the ED form was compared to the first prescriptions in the hospital ward that
were recorded in the chart. For T2, the prescriptions on the last hospitalization day recorded
on the chart were compared to the therapy list in the discharge letter. For T3, the prescriptions
in the discharge letter were compared to the first prescriptions in the local care setting that
were recorded on the chart. For T4, the prescription from the last care day were compared to
the prescriptions recorded in the discharge letter. Evaluation of medication discrepancies was
performed by the team. The doctor and the nurse, separately, analyzed transitional documen-
tation and reported all discrepancies detected, and all the discrepancies were subjected to the
pharmacists’ evaluation. Then, by re-evaluating the patients’ clinical history, the team defined
whether discrepancies were in line with the care pathway (intentional) or whether they were
the result of a clinical error (unintentional). In more complicated cases the doctor who had
treated the patient was consulted. Only, the unintentional discrepancies were recorded. Dis-
crepancies were classified as omissions of medication; errors/omissions of the drug name,
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dose, dosage, frequency and administration type; duplications; and interactions. The drugs
involved in the discrepancies were categorized by their mechanisms of action. This study
termed “not evaluable discrepancies” as the following: i) the patient was admitted to the hospi-
tal ward immediately without transitioning to the ED; and ii) there was no discharge letter
because the patient died or was transferred to the ED from a local care setting. The “not evalu-
able discrepancies” were always considered to be missing.
This study defined “lack of documentation” as any situation in which there was no trace of
a clinical document. As the “lack of a documentation” did not allow to assess the presence or
absence of discrepancies, we evaluated two possible hypotheses. In the first hypothesis, assum-
ing that “lack of documentation” was a “not evaluable discrepancies” was considered to be
missing; in the second hypothesis, “lack of documentation” was considered to be a discrepancy
with the aim of considering the worst possible scenario.
Statistical analysis
To automate statistical analysis, we developed a general and robust R [26] pipeline that pro-
cessed the input data through the following steps:
Data sources. The input data were presented to the pipeline as a csv file in which each
row represented a patient along with his or her drug discrepancies. Given this format, multiple
rows belonging to the same patient were allowed (e.g., a single patient might be discrepant for
more than one drug).
Data matrix columns contained several attributes used for stratification: personal attributes
(e.g., gender, age, nationality) and discrepancy attributes (e.g., missing or erroneously admin-
istered drugs) detailed for each transition of care. Moreover, during the preprocessing phase,
raw attributes have been combined into functions that allowed to compute derived stratifica-
tion values (e.g., the difference between hospital admission and discharge dates has been used
to compute the number of days a person has been hospitalized), which in turns resulted into
more meaningful data for further analysis steps.
Descriptive analysis. Preprocessed data have been analyzed in terms of cumulative analy-
sis and descriptive analysis. In the cumulative analysis we computed the global discrepancy
assessment, by taking into account multiple discrepancies (when available) for every single
patient, which resulted in 398 rows, one for every combination of a patient and a specific dis-
crepancy. In the latter analysis, we instead resorted to a patient-centric analysis. We therefore
merged multiple discrepancies of a single patient in a single row, thus reducing the database to
366 rows, one for each patient.
The pipeline produced as output two files as follows: i) cumulative analysis, and, ii) descrip-
tive analysis. The first file, cumulative analysis, contained for each transition of care the stratifi-
cation in terms of categories. The figures in the output file were expressed as cumulative value
and relative percentage over the totals. In the descriptive analysis output file, all the database
columns of interest were analyzed according to their nature. Categorical variables have been
stratified, while numerical variables have been analyzed in terms of statistical distribution
computing their mean, standard deviation and quartile distribution. Some numerical variables
that allowed for further categorization (e.g., age) have also been factorized into groups (i.e., age
groups) in order to simplify the following odds ratio analysis. Moreover, patients with “lack of
documentation” have been analyzed in two different hypotheses depicted above. To obtain
more consistent and conservative measures "not evaluable discrepancies" patients have been
programmatically removed.
Stratification & risk analysis. After the descriptive analysis, the pipeline automatically
computed a confusion matrix for each categorical variable in order to perform significance
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tests, and data were prepared in a convenient fashion for further odds ratio analysis. Confusion
matrices were then corrected by evaluating numerosity constraints and discarding low abun-
dance strata (fewer than 8 elements) in order to reach sufficient significance in the statistical
tests. Both the Chi-Square test (high numerosity strata) and Fisher exact test (low numerosity
strata) were performed. For computing the drug discrepancy odds ratio for each stratum, we
defined a control value to be used as a reference for each confusion matrix, and we used the
strata with the lowest marginal probability as a control (i.e., with odds ratio = 1) and mapped
the other strata against this one, guaranteeing that all of the other odds ratios were greater than
1. An output file summarizes every stratification in terms of its odds ratio along with 95% con-
fidence intervals and the p-value of both the chi-square and Fisher’s exact tests.
The study was approved by Ethics Committee of the Turin territory, Prot. N. 0012774,
August 1, 2016. An informed written consent was obtained in agreement with Authorization
on processing personal data GU n. 302, December 27, 2013. The patients’ private health infor-
mation (PHI) was ensured by the de-identification of data.
Results
Between July 2015 and July 2016, 366 patients met the inclusion criteria and were included in
the study. The mean (SD) age of the patients was 80.77 (10.66) years, and 57.92% were female.
Table 1 lists the patient characteristics.
Most (93.72%, N = 343) of the enrolled patients were from the emergency department,
while 6.28% (N = 23) had a planned hospital admission.
Table 1. Patients’ characteristics (N = patients).
N = 366 %
Sex Female 212 57.92
Age <=65 35 9.56
66–84 200 54.64
>=85 131 35.79
Nationality Italian 359 98.09
Romanian 3 0.82
Non -EU 4 1.08
Pathology Fractures and orthopedic implant complications 91 24.86
Vertebral-cerebral vasculopathy and infarct / intracranial hemorrhages 41 11.20
Cardiovascular diseases 34 9.29
Respiratory tract infections 23 6.28
Dehydration, heat effects, hydro-electrolyte imbalance 18 4.92
Dementia and delirium 17 4.64
Solid tumors 15 4.10
Septicemia 15 4.10
Other 112 30.67
Non-EU includes the following nationalities: Nigerian, Chinese, Ethiopian, Moroccan. Each nationality has a unit value (N = 1; 0.27%)
The "”other"” category includes the followings:
Osteoarthritis and cervical spondylosis, asthma and respiratory failure (n = 14; 3.83%); urinary tract infections (n = 8; 19.2%); pulmonary embolism, gastrointestinal
infections, nephrotic syndrome, genitourinary diseases and renal failure (n = 6; 1.64%); contusions, intracranial trauma, gastritis and gastroduodenal ulcers (n = 4;
9.1%); anemia, depression and other mental disorders, hemiplegia, hemiparesis, hepatitis, hepatic encephalopathy, unspecified infection, esophageal disease,
rhabdomyolysis, lymphatic and hematological tumors, and pressure ulcers (n = 3; 0.82%); bowel obstruction, gastrointestinal bleeding, and syncope (n = 2; 0.55%);
ascites, diabetes, rashes, nose and throat infections, central nervous system infections, skin infections, neuropathy, muscle disease, abdominal aortic aneurysm, syphilis,
thyroiditis, and pleural effusion (n = 1; 0.27%); and missing diagnoses (n = 5; 1.37%).
https://doi.org/10.1371/journal.pone.0191028.t001
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Of the participants, 43.44% were admitted to internal medicine, 27.05% to orthopedics,
18.58% to geriatrics, 8.74% to neurology, 1.09% to surgery, 0.55% to cardiology and 0.55% to
the intensive care unit. The patients’ hospital discharge rates were 42.35% from internal medi-
cine, 27.32% from orthopedics, 19.67% from geriatrics and 10.66% from neurology. Addition-
ally, 36.06% of patients were admitted to rehabilitation settings, 34.43% to supported discharge
settings, 24.04% to long-stay care and 5.46% to integrated home care (ADI) (Fig 1).
First hypothesis: “lack of documentation” was considered to be missing
Considering the first hypothesis, the total number of discrepancies was 104; pharmacological
discrepancies involved 94 patients, so 25.68% of the total number of patients had at least one
discrepancy. The most frequent type of discrepancy was omission of medication (N = 74;
71.15%) (see Table 2).
Furthermore, the most frequent category of drugs involved in the discrepancy was “proton
pump inhibitors” (N = 11; 11.34%) (see Table 3).
Table 4 shows the association between the presence of 1 or more pharmacological discrep-
ancies in each transition and the independent variables (see Statistical Analysis). In this first
hypotheses, no variables were significantly associated with discrepancies at the first, second
and third transition (Table 4). By contrast, only T4 associations were significant: discharge
from a specific local care setting was associated with a discrepancy (p = 0.045), and the length
of stay was a statistically significant variable (p<0.001). Gender also appears to be associated
with drug discrepancies upon the fourth transition (p = 0.009).
Fig 1. Number of patients sampled in the care pathway through health facilities. T1: Hospital admission T2: Hospital discharge T3: Admission into
local care setting T4: Discharge from local care setting.
https://doi.org/10.1371/journal.pone.0191028.g001
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Table 2. Type of medication discrepancy (N = discrepancies).
First Hypothesis
(N = 104)
Second Hypothesis
(N = 218)
N % N %
Omission of medication 74 71.15 74 33.94
Error / omission of medication name 9 8.65 9 4.13
Error / omission of medication dose 11 10.58 11 5.05
Error / omission of drug dose 10 9.62 10 4.59
Lack of documentation - - 114 52.29
https://doi.org/10.1371/journal.pone.0191028.t002
Table 3. Drug categories involved in at least one discrepancy, first hypothesis (N = frequencies).
N = 97 %
Proton pump inhibitors 11 11.34
Diuretics, ACE inhibitors and angiotensin receptor blockers 10 10.31
Antithrombotics 9 9.28
Folic acid 6 6.19
Beta-blockers 6 6.19
Hyperuricemia reducers 6 6.19
Anxiolytics and antidepressants 5 5.15
Antiepileptics 5 5.15
Statins 5 5.15
Other
 The “other” category includes the followings: alpha blockers and 5-alpha reductase inhibitors, thyroid hormone,
and steroids (n = 4; 4.12%); bronchodilators (n = 3; 3.09%); antihypertensive REC alpha, calcium and vitamin D,
iron, prepared glaucoma and mitotic (n = 2; 2.6%); and painkiller, antidopaminergics, anti lithogenics, antimalarials,
antiparkinsonians, antivirals, acetyl-cholinesterase inhibitors, hypoglycemic, laxatives, nitrates, and psychostimulants
(n = 1, 1.3%)
https://doi.org/10.1371/journal.pone.0191028.t003
Table 4. P-value of the chi square test (N = patients).
Hypothesis 1 Hypothesis 2
Variable T1
(N = 308)
T2
(N = 366)
T3
(N = 317)
T4
(N = 298)
T1
(N = 329)
T2
(N = 366)
T3
(N = 356)
T4
(N = 332)
Age p = 0.856 p = 0.796 p = 0.217 p = 0.411 p = 0.481 p = 0.799 p = 0.296 p = 0.27
Gender p = 0.855 p = 0.84 p = 0.139 p = 0.009 p = 0.66 p = 0.846 p = 0.767 p = 0.049
Length of stay (days) in Hospital ward/Local
care setting
― p = 0.493 ― p<0.001 ― p = 0.499 ― p = 0.001
Changing ward Assignment ― p = 1 ― ― ― p = 1 ― ―
Hospital ward admission p = 0.118 ― ― ― p = 0.188 ― ― ―
Hospital ward discharge ― p = 0.544 p = 0.119 ― ― p = 0.547 p = 0.001 ―
Local care setting admission ― ― p = 0.374 ― ― ― p<0.001
Local care setting discharge ― ― ― p = 0.045 ― p = 0.23
Second Hypothesis
https://doi.org/10.1371/journal.pone.0191028.t004
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Finally, Table 5 shows the odds ratios at care transitions. Considering the first hypothesis,
the following three variables were associated with a higher risk of discrepancies for the
patients: long-stay care setting discharge [OR 2.59 (1.042–6.464)], and length of stay of or less
than 10 days [OR 11.43 (4.263–30.639)] and between 11 and 30 days [OR 3.72 (1.532–9.037)]
at T4.
Second hypothesis: “lack of documentation” was considered a discrepancy
Considering the second hypothesis, the total number of discrepancies was 218; 114 were from
a lack of documentation. The pharmacological discrepancies involved 160 patients, so 43.72%
had at least one discrepancy. Table 4 shows that no variables were significantly associated with
discrepancies at T1 and T2 (Table 4). By contrast, the T3 and T4 associations were significant.
The hospital ward discharge and the local care setting admission in the third transition
were associated with discrepancies (p = 0.001 and p<0.001, respectively). Finally, the length of
stay and gender were significantly correlated with pharmacological discrepancies in the fourth
transition (p = 0.001 and p = 0.049, respectively).
Table 5 shows that integrated home care admission [OR 17 (3.942–76.416)] and patients
discharged from orthopedic ward [OR 4 (1.163–14.522)] had higher odds of discrepancy com-
pared to long stay care settings and patients discharged from neurology respectively in T3.
Table 5. Risk profile at care transitions, odds ratio (95% CI).
Hypothesis 1 Hypothesis 2
T3 T4 T3 T4
Genderǂ
M 2.73 (0.804–9.257) 2.63 (1.239–5.561) 1.12 (0.617–2.035) 1.74 (1.016–2.988)
F 1 (0.246–4.062) 1 (0.436–2.293) 1 (0.569–1.758) 1 (0.58–1.723)
Length of stay (days) in local care setting
10 ― 11.43 (4.263–30.639) ― 4.69 (2.015–10.923)
11–30 ― 3.72 (1.532–9.037) ― 2.16 (1.119–4.185)
31 ― 1 (0.453–2.209) ― 1 (0.613–1.631)
Local care setting admission
Integrated home care ― ― 17.36 (3.942–76.416) ―
Rehabilitation 1 (0.138–7.229) ― 2.57 (1.056–6.261) ―
Supported discharge 2.89 (0.571–14.647) ― 1.45 (0.559–3.745) ―
Long-stay care 1.33 (0.184–9.667) ― 1 (0.336–2.98) ―
Hospital ward discharge
Internal medicine 1 (0.245–4.079) ― 1.13 (0.306–4.181) ―
Orthopedics ― 4.11 (1.163–14.522) ―
Geriatrics 3.57 (0.971–13.119) ― 2.07 (0.533–8.026) ―
Neurology 1.98 (0.338–10.883) ― 1 (0.189–5.289) ―
Local care setting discharge
Integrated home care ― ― ― ―
Rehabilitation ― 1.04 (0.414–2.614) ― 1 (0.495–2.02)
Supported discharge ― 1 (0.381–2.627) ― 1.11 (0.542–2.271)
Long-stay Care ― 2.59 (1.042–6.464) ― 1.88 (0.88–3.962)
Second Hypothesis
ǂ F: Female; M: Male
https://doi.org/10.1371/journal.pone.0191028.t005
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Finally, a length of stay of or less than 10 days and between 11 and 30 days was associated with
an increased risk of discrepancies [OR 4.69 (2.015–10.932); OR 2.16 (1.119–4.185) respec-
tively] in the fourth transition.
Discussion
To our knowledge this study is the first to consider the complete pathway for patients from
hospital admission to local care setting discharge. The literature shows that studies on medica-
tion reconciliation have focused on a single point of care transition.
Our study demonstrates that 25.68% and 43.72% of patients had at least one medication dis-
crepancy in the first and second hypotheses, respectively. This rate of medication discrepancy
is significant because it concerns the medication discrepancies during the entire care pathway
from hospital admission to a local care setting discharge and it is lower than that from most of
the reviewed studies, which focused on one transition care, especially in hospital transitions.
Indeed, the reported discrepancies, involved 25%-70% of hospital admissions and 33%-96% at
hospital discharge [4,6,20–22]. Our results may be influenced by the fact that the Italian health-
care system is set up to manage the continuity of care and to reduce fragmentation. The use of
units (NOCC; NDCC) that facilitate the transition from hospital care to local care settings
along with the presence of structured documentation upon some transitions and the participa-
tion of pharmacists, play in favor of low drug discrepancies. This suggestion justifies the best
result compared to that reported from other countries with a different healthcare system such
as the US [22,27] and Canada [6,20].
Previous studies have shown that the omission of a medication [6] and incomplete prescrip-
tions [20] were the most common discrepancies. These findings are consistent with those of
our study, which reported the omission of medication as the most frequent type of discrep-
ancy. Our findings highlight that the variables associated with the risk of discrepancy change
from hypothesis 1 to hypothesis 2. Considering “lack of documentation” as missing (hypothe-
sis 1), there is only a statistically significant association at the fourth transition, particularly
between the local care setting discharge and the onset of discrepancies. Moreover, our findings
show that a long-stay care discharge has an increased risk of drug discrepancy. This result may
be explained by the multiple organizations of care settings and their critical issues of work
environment [28], by the high number of drugs, and by the frequent lack of standardized pro-
cedures for pharmacological reconciliation in this setting. This observation is consistent with
those of previous studies that underlined the importance of a drug reconciliation module that
keeps track of the changes in therapy for patients who are discharged to long-stay care settings
[22,29,30].
Considering the second hypothesis, both hospital ward discharges and local care setting
admissions at the third transition are significantly associated with the onset of discrepancies.
Our results demonstrate a higher risk of discrepancy upon discharge from the orthopedic
ward. This result may be attributed to the observation that this ward did not report a list of
drugs in the discharge letter; instead the therapy sheet was included in the clinical chart, which
should be sent to the local care setting. However, this practice was not effective because the
therapy sheet was frequently not sent during the care transition. Consistent with the findings
of Monfort et al., who presented similar results in which the discharge prescriptions from an
orthopedic ward were often incomplete or the transmission of medication information at dis-
charge was often lacking [31], we suggest the use of a structured medication reconciliation
form. Considering again the second hypothesis, at the third transition, the local care setting
admission is associated with medication discrepancies. Admission to an Integrated home care
carries the highest risk of discrepancy. This result may be affected by the poorly structured or
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missing documentation. As reported in the study by Cua et al., documentation of medication
changes, their rationale, and whether changes are temporary or permanent are often lacking
[32]. A systematic review conducted by Tam et al., stressed that the prevailing pharmacological
discrepancy in the home situation is the lack of a drug list [17]. Furthermore, a 2009 review
conducted by Bayoumi et al. in primary care demonstrated that the lack of quality information
impacts medication reconciliation [33]. The documents in the home situation may have disad-
vantages of bad handwriting, delays in preparation and missing or incorrect information,
increasing the risk of drug discrepancies [34].
A noteworthy result is the risk of drug discrepancy in relation to the length of stay in local
care settings, which indicates that there is a higher risk of discrepancy for a10 days length of
stay than for longer periods. Comparison of this result with those of other studies are nega-
tively affected by variations in the point of transition. Indeed, few studies in the literature that
evaluate the correlation between the length of stay and risk of drug discrepancies focus on the
length of stay in a hospital and do not evaluate the local care setting. One study indicates that
the possible occurrence of discrepancies is 1.70-fold greater for patients who remain hospital-
ized for a longer time, but this result is not significant (p = 0.065) [22]. An explanation for a
lower risk with a longer stay could be that spending more time in the local settings could
improve the understanding of the patient’s condition and result in more attention to his or her
therapy.
The lack of communication among professional workers upon care transitions, identified
as “lack of documentation”, is one of the issues identified in our study. The importance of
structured communication, which could be a part of standardized reconciliation procedures, is
a key factor for the continuity of pharmacological therapy [27,35]. There are some strategies to
improve the quality of the reconciliation process, which can be extended to any context. First,
the study of Whittington et al. detected an increase of 55% in the accuracy of the reconciliation
process by introducing a qualified nursing staff and pharmacist staff [36]. Therefore, the pro-
cess should be performed in an integrated and multidisciplinary manner to support correct
admission and discharge medication reconciliation. Moreover, many studies have reported on
the pharmacist as a professional reference in the reconciliation process and have encouraged
teamwork among medical doctors, nurses and pharmacists [7,37–39]. Second, a computerized
system could facilitate the electronic collection and transfer of medication information from
the time of hospital admission to the local care setting discharge, thus reducing the risk of drug
discrepancies [3,40–42]. Finally, if the computerization of systems is not possible, a standard-
ized medication reconciliation tool should be introduced to keep track of patient therapy
throughout the care transitions [30,43,44].
There are some limitations in our study. First, the reconciliation process is retrospectively
assessed. Thus, it was not possible to retrospectively assess whether the drugs involved in the
discrepancies were attributable to the fault of the reconnaissance or reconciliation processes;
therefore, they were evaluated together. Additionally, it was not possible to measure the poten-
tial clinical impact, such as adverse events. Second, the lack of clinical documentation could
have limited our analysis because it could not definitively be evaluated whether all cases with a
lack of documentation involved medication discrepancies. Third, because of the small sample
size, the magnitude of the effect of many of the associations seen cannot be determined with
any accuracy. The large size of the confidence intervals seen for major associations indicates
that the point estimates for effect size are not likely to be accurate. Finally, the generalizability
of our findings could be limited because the results are affected by the type of healthcare sys-
tem and by the efforts ASLTO2 has made to favor the integration of multiple care settings.
In conclusion, the rate of medication discrepancies across the entire care pathway from
hospital admission to a local care setting discharge is low in comparison with results focused
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PLOS ONE | https://doi.org/10.1371/journal.pone.0191028 January 12, 2018 10 / 13
on just one care transition. However, this result can be improved, as the local care settings
unfortunately have a high lack of communication among professionals with missing documen-
tation, especially in the integrated home care setting. This study suggests that an integrated
health care system, such as the Italian system, may influence the prevalence of discrepancies,
and highlights the need for structured multidisciplinary and, if possible, computerized medica-
tion reconciliation to prevent medication discrepancies and improve the quality of medical
documentation.
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